{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:20:05Z","timestamp":1792682405423,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018202","name":"AIRC","doi-asserted-by":"publisher","award":["IG23009"],"award-info":[{"award-number":["IG23009"]}],"id":[{"id":"10.13039\/100018202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018202","name":"AIRC","doi-asserted-by":"publisher","award":["IG27233"],"award-info":[{"award-number":["IG27233"]}],"id":[{"id":"10.13039\/100018202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>No effective therapies are available for patients with advanced adrenocortical carcinoma (ACC) progressing after standard therapy: EDP (etoposide, adriamycin, and cisplatin) and mitotane (EDP-M regimen). These patients have poor prognosis with a median life expectancy of 6-7 months. Immunotherapy in this setting is promising. Concomitant chemotherapy administration can enhance the efficacy of immunotherapy, as demonstrated in other malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This retrospective study aims to explore the activity of a combination of cisplatin and nivolumab administered to patients with ACC who have previously undergone chemotherapy and mitotane treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Cisplatin, 25\u2005mg\/m2 on day 1, and nivolumab, 240\u2005mg on day 2, every 2 weeks, were administered to advanced\/metastatic ACC with disease progression to EDP-M regimen plus\/minus other chemotherapeutic regimens. The primary endpoint was the disease response according to RECIST. Secondary endpoints were clinical benefit, disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three patients were enrolled between January 2023 and March 2025. The median follow-up was 15.1 months. Eight patients [34.8% (95% CI, 15.3%-54.2%)] obtained a partial response and 4 patients (17.3%) a stable disease; therefore, 12 patients (52.2%) obtained a clinical benefit. The DCR after 6 months was obtained in 39.1% [95% CI, 19.7%-61.5%] of patients. The median PFS was 4.3 months [95% CI, 3.9-13.0], and the median OS was 18.9 months [95% CI, 15.8-not reached]. Chemo\u2013immunotherapy combination was well tolerated, and most toxicities were limited to grade G1-2 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria. One patient discontinued treatment after 1 cycle, due to grade 3 immune-related hepatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of cisplatin and nivolumab is an active regimen in advanced, previously treated, ACC patients. The long survival achieved in this patient population with a poor prognosis is promising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag008","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:19:37Z","timestamp":1768220377000},"page":"199-207","source":"Crossref","is-referenced-by-count":4,"title":["Chemo\u2013immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-122X","authenticated-orcid":false,"given":"Marta","family":"Lagan\u00e0","sequence":"first","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3248-6655","authenticated-orcid":false,"given":"Sara","family":"Rodella","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Lorenzo","family":"Bettini","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Esposito","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Department of Molecular & Translational Medicine, Section of Pharmacology, Universit\u00e0 degli Studi di Brescia , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Radiology, ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Tamburello","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Department of Molecular & Translational Medicine, Section of Pharmacology, Universit\u00e0 degli Studi di Brescia , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Tinti","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Radiology, ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, Universit\u00e0 degli Studi di Brescia , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Casole","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Surgery, Department of Clinical and Experimental Sciences, Universit\u00e0 degli Studi di Brescia, ASST-Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7635-1179","authenticated-orcid":false,"given":"Guido Alberto Massimo","family":"Tiberio","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Surgery, Department of Clinical and Experimental Sciences, Universit\u00e0 degli Studi di Brescia, ASST-Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Department of Molecular & Translational Medicine, Section of Pharmacology, Universit\u00e0 degli Studi di Brescia , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[{"name":"Adrenal Cancer Unit, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]},{"name":"Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"11","key":"2026030204013283000_lvag008-B1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"2026030204013283000_lvag008-B2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026030204013283000_lvag008-B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026030204013283000_lvag008-B4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"23","key":"2026030204013283000_lvag008-B5","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2026030204013283000_lvag008-B6","doi-asserted-by":"publisher","first-page":"624102","DOI":"10.3389\/fendo.2021.624102","article-title":"Clinical prognostic factors in patients with metastatic adrenocortical carcinoma treated with second line gemcitabine plus capecitabine chemotherapy","volume":"12","author":"Grisanti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026030204013283000_lvag008-B7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026030204013283000_lvag008-B8","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"issue":"10","key":"2026030204013283000_lvag008-B9","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026030204013283000_lvag008-B10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026030204013283000_lvag008-B11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026030204013283000_lvag008-B12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2026030204013283000_lvag008-B13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"2026030204013283000_lvag008-B14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026030204013283000_lvag008-B15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cancers16050900","article-title":"The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: a systematic review and meta-analysis","volume":"16","author":"Ababneh","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"36","key":"2026030204013283000_lvag008-B16","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.2217\/fon-2020-0686","article-title":"The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma","volume":"16","author":"Grisanti","year":"2020","journal-title":"Future Oncol"},{"key":"2026030204013283000_lvag008-B17","doi-asserted-by":"publisher","first-page":"835502","DOI":"10.3389\/fonc.2022.835502","article-title":"Translational learnings in the development of chemo-immunotherapy combination to bypass the cold tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"12","author":"Kaplon","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"2026030204013283000_lvag008-B18","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030204013283000_lvag008-B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030204013283000_lvag008-B20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/cancers12061395","article-title":"Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria","volume":"12","author":"Ambrosini","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026030204013283000_lvag008-B21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Participants of the fifth ovarian cancer consensus conference. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2026030204013283000_lvag008-B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","article-title":"Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma","volume":"61","author":"Claps","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"2026030204013283000_lvag008-B23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2026030204013283000_lvag008-B24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2026030204013283000_lvag008-B25","doi-asserted-by":"publisher","first-page":"10371","DOI":"10.1038\/s41467-024-54661-9","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"issue":"22","key":"2026030204013283000_lvag008-B26","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/1078-0432.CCR-25-2143","article-title":"Cabozantinib plus atezolizumab in advanced, progressive endocrine malignancies: a multi-cohort, basket, phase II trial (CABATEN\/GETNE-T1914)","volume":"31","author":"Capdevila","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026030204013283000_lvag008-B27","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.esmoop.2025.104355","article-title":"Reintroduction of platinum-based chemotherapy \u00b1 mitotane for advanced adrenocortical cancer: single-center retrospective trial","volume":"10","author":"Zhulikov","year":"2025","journal-title":"ESMO Open"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag008\/66406099\/lvag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/199\/66406099\/lvag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/199\/66406099\/lvag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:01:38Z","timestamp":1772442098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/2\/199\/8425130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag008","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,14]]}}}